Addendum to British Society for Haematology Guideline for the management of mantle cell lymphoma, 2018 (Br. J. Haematol. 2018; 182: 46–62): Risk assessment of potential CAR T candidates receiving a covalent Bruton tyrosine kinase inhibitor for relapsed/refractory disease. (27th July 2022) - O'Reilly, Maeve A.; Sanderson, Robin; Wilson, William; Iyengar, Sunil; Lambert, Jonathan; McCulloch, Rory; Eyre, Toby A.; ,